148 related articles for article (PubMed ID: 37730526)
1. Local Therapy on Clinically Lymph Node-positive Prostate Cancer: A Systematic Review and Meta-analysis.
Yaow CYL; Lee HJ; Teoh SE; Chong RIH; Ng TK; Tay KJ; Ho H; Law YM; Tuan J; Yuen J; Chen K
Eur Urol Oncol; 2024 Jun; 7(3):355-364. PubMed ID: 37730526
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer.
Ventimiglia E; Seisen T; Abdollah F; Briganti A; Fonteyne V; James N; Roach M; Thalmann GN; Touijer K; Chen RC; Cheng L
Eur Urol Oncol; 2019 May; 2(3):294-301. PubMed ID: 31200844
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis.
Seisen T; Vetterlein MW; Karabon P; Jindal T; Sood A; Nocera L; Nguyen PL; Choueiri TK; Trinh QD; Menon M; Abdollah F
Eur Urol; 2018 Mar; 73(3):452-461. PubMed ID: 28890245
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
[TBL] [Abstract][Full Text] [Related]
5. Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.
Marra G; Valerio M; Heidegger I; Tsaur I; Mathieu R; Ceci F; Ploussard G; van den Bergh RCN; Kretschmer A; Thibault C; Ost P; Tilki D; Kasivisvanathan V; Moschini M; Sanchez-Salas R; Gontero P; Karnes RJ; Montorsi F; Gandaglia G;
Eur Urol Oncol; 2020 Oct; 3(5):565-581. PubMed ID: 32933887
[TBL] [Abstract][Full Text] [Related]
6. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.
Gakis G; Boorjian SA; Briganti A; Joniau S; Karazanashvili G; Karnes RJ; Mattei A; Shariat SF; Stenzl A; Wirth M; Stief CG
Eur Urol; 2014 Aug; 66(2):191-9. PubMed ID: 23735200
[TBL] [Abstract][Full Text] [Related]
7. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
Gandaglia G; Soligo M; Battaglia A; Muilwijk T; Robesti D; Mazzone E; Barletta F; Fossati N; Moschini M; Bandini M; Joniau S; Karnes RJ; Montorsi F; Briganti A
Eur Urol; 2019 May; 75(5):817-825. PubMed ID: 30409676
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
9. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
10. Association between Radical Prostatectomy and Survival in Men with Clinically Node-positive Prostate Cancer.
Sarkar RR; Bryant AK; Parsons JK; Ryan ST; Karim Kader A; Kane CJ; McKay RR; Sandhu A; Murphy JD; Rose BS
Eur Urol Oncol; 2019 Sep; 2(5):584-588. PubMed ID: 31411995
[TBL] [Abstract][Full Text] [Related]
11. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
12. Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy: A meta-analysis.
Guo L; Zhu Z; Zhang X
Medicine (Baltimore); 2020 Mar; 99(10):e19153. PubMed ID: 32150055
[TBL] [Abstract][Full Text] [Related]
13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis.
Wang Z; Ni Y; Chen J; Sun G; Zhang X; Zhao J; Zhu X; Zhang H; Zhu S; Dai J; Shen P; Zeng H
World J Surg Oncol; 2020 Feb; 18(1):42. PubMed ID: 32093688
[TBL] [Abstract][Full Text] [Related]
15. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis.
Greenberger BA; Zaorsky NG; Den RB
Eur Urol Focus; 2020 Mar; 6(2):404-418. PubMed ID: 31813810
[TBL] [Abstract][Full Text] [Related]
18. Mid-term oncologic outcomes of radical prostatectomy in lymph node metastatic prostate cancer patients.
Berchiche W; Long Depaquit T; Baboudjian M; Barret É; Rozet F; Cathelineau X; Bastide C
Prog Urol; 2023 Aug; 33(8-9):437-445. PubMed ID: 37248105
[TBL] [Abstract][Full Text] [Related]
19. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB
Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018
[TBL] [Abstract][Full Text] [Related]
20. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]